Common Contracts
57 similar Employment Agreement contracts by Immuneering Corp, Omega Therapeutics, Inc., Fractyl Health, Inc., others
Employment AgreementEmployment Agreement • March 1st, 2024 • Immuneering Corp • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated as of March 24, 2023, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Harold E. Brakewood (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 1st, 2024 • Immuneering Corp • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Mallory Morales (“Executive”) (collectively referred to herein as the “Parties” or
Employment AgreementEmployment Agreement • January 29th, 2024 • Fractyl Health, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of January 26, 2024, is made by and between Fractyl Health, Inc. a Delaware corporation (together with any successor thereto, the “Company”), and Jay Caplan (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • January 29th, 2024 • Fractyl Health, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of January 26, 2024, is made by and between Fractyl Health, Inc. a Delaware corporation (together with any successor thereto, the “Company”), and Harith Rajagopalan (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • January 29th, 2024 • Fractyl Health, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of January 26, 2024, is made by and between Fractyl Health, Inc. a Delaware corporation (together with any successor thereto, the “Company”), and Lisa Davidson (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • January 29th, 2024 • Fractyl Health, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of January 26, 2024, is made by and between Fractyl Health, Inc. a Delaware corporation (together with any successor thereto, the “Company”), and Sarah Toomey (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • November 7th, 2023 • Sight Sciences, Inc. • Surgical & medical instruments & apparatus • Delaware
This Employment Agreement (this “Agreement”), effective as of September 11, 2023 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Matthew Link (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • May 8th, 2023 • Sight Sciences, Inc. • Surgical & medical instruments & apparatus • California
This Employment Agreement (this “Agreement”), effective as of April 3, 2023 (the “Effective Date”), is made by and between Sight Sciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Alison Bauerlein (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 29th, 2023 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of February 2, 2023, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and John Bishop (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 22nd, 2023 • SQZ Biotechnologies Co • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 28, 2022, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Howard Bernstein, M.D.,Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective on November 30, 2022 (the “Effective Date”).
Employment AgreementEmployment Agreement • March 2nd, 2023 • Selecta Biosciences Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 9, 2022, is made by and between Selecta Biosciences, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Blaine Davis (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), and effective as of Nov. 28, 2022 (the “Effective Date”).
Employment AgreementEmployment Agreement • July 11th, 2022 • SQZ Biotechnologies Co • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 7, 2022, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Micah Zajic (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective as of July 11, 2022 (the “Effective Date”).
Employment AgreementEmployment Agreement • May 4th, 2022 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of February 03, 2022, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Kevin McManus (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). This Agreement shall be effective as of the date of execution by the Parties (the “Effective Date”).
Employment AgreementEmployment Agreement • May 4th, 2022 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of [ ], 2022, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Joshua Reed (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). This Agreement shall be effective as of the date of execution by the Parties (the “Effective Date”).
Employment AgreementEmployment Agreement • May 4th, 2022 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of March 18, 2022, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Ling Zeng (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”). This Agreement shall be effective as of the date of execution by the Parties (the “Effective Date”).
Employment AgreementEmployment Agreement • March 24th, 2022 • Rapid Micro Biosystems, Inc. • Laboratory analytical instruments • Massachusetts
This Employment Agreement (this “Agreement”), dated as of October 1, 2021 (the “Effective Date”), is made by and between Rapid Micro Biosystems, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Richard Keys (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 23rd, 2022 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of March 18, 2020, is made by and between Homology Medicines, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Paul Alloway, PhD, J.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and effective as of May 4, 2020 (the “Effective Date”).
Employment AgreementEmployment Agreement • March 23rd, 2022 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of September 1, 2021 (the “Effective Date”), is made by and between Homology Medicines, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Michael Blum (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 16th, 2022 • SQZ Biotechnologies Co • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of October 29, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and David First (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • March 16th, 2022 • SQZ Biotechnologies Co • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of October 29, 2020, is made by and between SQZ Biotechnologies Company, a Delaware corporation (together with any successor thereto, the “Company”), and Howard Bernstein, M.D., Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • March 9th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of April 27, 2020, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Corinne Noyes (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 9th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of June 20, 2020, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Robert E. Richard, Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 9th, 2022 • Lyra Therapeutics, Inc. • Surgical & medical instruments & apparatus • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 17, 2020, is made by and between Lyra Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Pamela Nelson (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 3rd, 2021 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”), dated as of January 29, 2021 (the “Effective Date”), is made by and between Seres Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and David Ege, Ph.D (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Immuneering Corp • Pharmaceutical preparations • California
This Employment Agreement (this “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Brett Hall, Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of common stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 24, 2021, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Roger Sawhney, M.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 25, 2021, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Mahesh Karande (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Immuneering Corp • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Biren Amin (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of common stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Immuneering Corp • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Scott Barrett, M.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of common stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Immuneering Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Michael Bookman (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of common stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Immuneering Corp • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), dated as of July 23, 2021, is made by and between Immuneering Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Benjamin Zeskind, Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of common stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • July 26th, 2021 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”), dated as of July 24, 2021, is made by and between Omega Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Thomas McCauley, Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • March 30th, 2021 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 3, 2020 (the “Effective Date”), is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and John Vavricka (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
Employment AgreementEmployment Agreement • March 30th, 2021 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 3, 2020, is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Wayne Foster (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective, if at all, upon the date of the closing of Company’s initial public offering of stock (“IPO”) pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the “Effective Date”).
Employment AgreementEmployment Agreement • March 30th, 2021 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 3, 2020 (the “Effective Date”), is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Janet Hammond, M.D., Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
